Overweight 123,821 172,971 157,623 103,326 155,090 130,052 842,883Obese class I 56,969 66,667 51,956 37,656 63,233 50,862 327,342Obese class II 18,763 21,762 17,649 11,111 14,442 13,461 97,190Obese class III 9,218 7,030 7,582 5,878 3,912 5,071 38,691Total 517,000 538,301 459,889 284,244 377,178 442,422 2,619,033% 16.43% 17.73% 16.78% 19.22% 21.63% 15.69% 17.69%By marriageBMI Married or common law Widowed Single Missing TotalMissing data 94,746 16,055 27,495 606 138,902Underweight 31,548 5,697 20,278 272 57,796Normal weight 666,071 117,145 330,127 2,886 1,116,229Overweight 591,330 88,224 159,677 3,652 842,883Obese class I 241,128 39,060 46,987 167 327,342Obese class II 67,197 10,259 19,376 358 97,190Obese class III 24,687 4,620 9,383 0 38,691Total 1,716,707 281,060 613,323 7,941 2,619,033% 19.40% 19.20% 12.40% 6.60% 17.70%ComorbiditiesCancerBMI No Yes TotalMissing data 135,674 2,890 138,564Underweight 55,897 1,899 57,796Normal weight 1,098,598 16,436 1,115,034Overweight 829,190 12,929 842,120Obese class I 321,470 5,704 327,173Obese class II 95,207 1,226 96,432Obese class III 36,620 2,071 38,691Total 2,572,656 43,155 2,615,810% 17.62% 20.86% 17.67%DiabetesBMI No Yes TotalMissing data 125,418 13,275 138,694Underweight 56,954 842 57,796Normal weight 1,091,785 24,020 1,115,805Overweight 806,890 35,784 842,674Obese class I 290,695 36,647 327,342Obese class II 83,742 12,346 96,089Obese class III 29,762 8,928 38,691Total 2,485,246 131,842 2,617,091% 16.26% 43.93% 17.66%<strong>Bariatric</strong> <strong>treatments</strong> <strong>for</strong> <strong>adult</strong> <strong>obesity</strong> 48
High blood pressureBMI No Yes TotalMissing data 112,341 25,742 138,082Underweight 53,676 3,988 57,664Normal weight 1,008,399 102,977 1,111,376Overweight 693,921 147,609 841,530Obese class I 236,279 89,361 325,640Obese class II 66,235 30,113 96,349Obese class III 22,911 15,669 38,581Total 2,193,762 415,459 2,609,222% 14.83% 32.53% 17.65%Heart diseaseBMI No Yes TotalMissing data 132,039 5,369 137,408Underweight 56,061 1,458 57,520Normal weight 1,091,358 23,449 1,114,807Overweight 806,570 34,488 841,058Obese class I 310,123 16,793 326,917Obese class II 90,425 5,299 95,725Obese class III 36,092 2,562 38,653Total 2,522,669 89,418 2,612,088% 17.31% 27.57% 17.66%By health regionBMISouth zoneCalgaryzone Central zoneEdmontonzoneNorthzone TotalMissing data 14,100 51,500 17,023 42,430 13,848 138,902Underweight 6,287 20,717 6,632 21,193 2,967 57,796Normal weight 75,163 457,974 122,154 362,993 97,945 1,116,229Overweight 64,160 316,738 110,391 253,193 98,401 842,883Obese class I 27,609 92,827 47,796 106,809 52,301 327,342Obese class II 7,943 33,353 13,560 28,335 13,999 97,190Obese class III 4,577 14,479 3,887 11,094 4,654 38,691Total 199,839 987,588 321,443 826,047 284,115 2,619,033% 20.08% 14.24% 20.30% 17.70% 24.97% 17.69%Notes:1. Source: Canadian Community <strong>Health</strong> Survey, 2007.2. The data presented are <strong>for</strong> Albertans aged 18 years and older.3. Missing data indicate those not responding to the survey questions.* % was calculated by dividing the sum <strong>of</strong> obese classes I, II, and III by total population in each category.** Numbers in brackets are the percentages <strong>of</strong> a total <strong>adult</strong> population <strong>of</strong> 2,619,032 in Alberta in 2007.<strong>Bariatric</strong> <strong>treatments</strong> <strong>for</strong> <strong>adult</strong> <strong>obesity</strong> 49
- Page 1 and 2:
Alberta STE ReportBariatric treatme
- Page 3 and 4:
Alberta STE ReportBariatric treatme
- Page 5 and 6:
EXECUTIVE SUMMARYSocial and System
- Page 7 and 8:
Three surgical procedures—adjusta
- Page 9:
Costs of Bariatric Surgery and Pote
- Page 12 and 13:
Regulatory status .................
- Page 14 and 15:
TABLES AND FIGURESSection One: Soci
- Page 16 and 17:
ABBREVIATIONSAll abbreviations that
- Page 18 and 19:
LYMmMAMDMUHCNANHLBINHSNICENIHNNHNPH
- Page 20 and 21:
Bariatric physician: a licensed Doc
- Page 22 and 23: High-density lipoprotein (HDL): a f
- Page 24 and 25: Very-low-calorie diet (VLCD): a die
- Page 26 and 27: Additional Internet searches were c
- Page 28 and 29: This report addresses obesity in ad
- Page 30 and 31: Many systemic factors have been ide
- Page 32 and 33: Severe obesity is associated with d
- Page 34 and 35: eport their height and under-report
- Page 36 and 37: Also using self-reported data from
- Page 38 and 39: An examination of overall obesity d
- Page 40 and 41: Table S.2 presents the associationa
- Page 42 and 43: • have multiple focal points and
- Page 45 and 46: The main problem in any weight mana
- Page 47: food, and a negative body image. As
- Page 50 and 51: directly causes death. 61 To the ex
- Page 52 and 53: The addition of a selected pharmaco
- Page 54 and 55: lack of formal training in nutritio
- Page 56 and 57: slightly more likely to have prescr
- Page 58 and 59: selection criteria, have facilities
- Page 60 and 61: Barriers to using appropriate baria
- Page 62 and 63: Overview of adult obesityOver the p
- Page 64 and 65: the need for regular physical activ
- Page 66 and 67: phenylpropanolamine/25. Sibutramine
- Page 68 and 69: Complianceand AdherenceDemand andut
- Page 70 and 71: Aetna Clinical PolicyBulletinswww.a
- Page 74 and 75: REFERENCES1. 2006 Canadian clinical
- Page 76 and 77: 34. Gostin LO. Fast and supersized:
- Page 78 and 79: 69. Klarenbach S, Padwal R, Wiebe N
- Page 80 and 81: 105. Hill JO, Thompson H, Wyatt H.
- Page 82 and 83: 141. Ross R, Bradshaw AJ. The futur
- Page 84 and 85: 172. Arkinson J, Ji H, Fallah S, Pe
- Page 86 and 87: This section will address a set of
- Page 88 and 89: dietary therapy is to reduce total
- Page 90 and 91: Additional benefits of exercise ove
- Page 92 and 93: medications that inhibit intestinal
- Page 94 and 95: Rimonabant may be considered for pa
- Page 96 and 97: Long-term complications are specifi
- Page 98 and 99: Devices used for bariatric surgeryH
- Page 100 and 101: Description of the Included Systema
- Page 102 and 103: AEs for sibutramineAs compared to a
- Page 104 and 105: Evidence on Efficacy/EffectivenessW
- Page 106 and 107: Table T.7: Effects of behavioural t
- Page 108 and 109: SurgeryDescription of the included
- Page 110 and 111: follow-up time was 3 years. Results
- Page 112 and 113: group as compared to the VBG group.
- Page 114 and 115: The authors identified many methodo
- Page 116 and 117: The investigators pointed out that
- Page 118 and 119: approximately 3 to 5 kilograms. For
- Page 120 and 121: for studies with a mean age of part
- Page 122 and 123:
Examining whether use of any of the
- Page 124 and 125:
Evidence from placebo-controlled cl
- Page 126 and 127:
colorectal or gastroesophageal or f
- Page 128 and 129:
Web of ScienceISI Interface License
- Page 130 and 131:
AMA Clinical PracticeGuidelineswww.
- Page 132 and 133:
critical appraisal of the included
- Page 134 and 135:
APPENDIX T.B: EXCLUDED STUDIESTable
- Page 136 and 137:
Padwal R, Li SK, Lau DC. Long-term
- Page 138 and 139:
Quality subsection 1: At least MEDL
- Page 140 and 141:
Quality subsection 5a:Study quality
- Page 142 and 143:
Partially reported: The study types
- Page 144 and 145:
Table T.C.1: Results of quality ass
- Page 146 and 147:
Table T.C.1: Results of quality ass
- Page 148 and 149:
APPENDIX T.D: CHARACTERISTICS OF SY
- Page 150 and 151:
Table T.D.1: Characteristics of the
- Page 152 and 153:
Table T.D.1: Characteristics of the
- Page 154 and 155:
Table T.D.2: Characteristics of the
- Page 156 and 157:
APPENDIX T.E: EVIDENCE TABLE ON SAF
- Page 158 and 159:
Serious surgical complicationsSurgi
- Page 160 and 161:
LSGmMAMDNAnssORQoLRCTRDRRRYGBSBPTGV
- Page 162 and 163:
Table T.F.1-2: Weight loss - Behavi
- Page 164 and 165:
Table T.F.1-4: Weight loss - Surger
- Page 166 and 167:
Table T.F.2: Quality of life (QoL)
- Page 168 and 169:
Curioni & Lourenco 2005 58Cholester
- Page 170 and 171:
Table T.F.3-3: Risk factors/comorbi
- Page 172 and 173:
Table T.F.3-5: Long-term effects of
- Page 174 and 175:
Maciejewski et al., 2005 65Avenell
- Page 176 and 177:
Table T.G.2: Effects of bariatric s
- Page 178 and 179:
Table T.G.4: Effects of bariatric s
- Page 180 and 181:
18. Cerulli J, Lomaestro BM, Malone
- Page 182 and 183:
50. Health Canada Drug Product Data
- Page 184 and 185:
SECTION THREE: ECONOMIC EVALUATIONC
- Page 186 and 187:
Definition of bariatric surgical pa
- Page 188 and 189:
etween surgical interventions, the
- Page 190 and 191:
concluded that adding orlistat to L
- Page 192 and 193:
Weight management program (WMP) ver
- Page 194 and 195:
groups. Compared with standard care
- Page 196 and 197:
Results from Analysis of Provincial
- Page 198 and 199:
DiscussionThe objectives of the eco
- Page 200 and 201:
surgical suites, and so on. The bud
- Page 202 and 203:
APPENDIX E.A: LITERATURE SEARCH SUM
- Page 204 and 205:
CRD Databases(DARE, HTA & NHS EED)h
- Page 206 and 207:
Web of ScienceISI Interface License
- Page 208 and 209:
NEOS Librarywww.library.ualberta.ca
- Page 210 and 211:
Table E.A.2: Evidence table of revi
- Page 212 and 213:
ResultHealth outcomesCostsMarginal
- Page 214 and 215:
CostsMarginal analysisThe cost anal
- Page 216 and 217:
Time Horizon/discount rateCurrency/
- Page 218 and 219:
Objectivestudy perspective: society
- Page 220 and 221:
ResultHealth outcomesCostsMarginal
- Page 222 and 223:
ResultHealth outcomesCostsMarginal
- Page 224 and 225:
S4Economic burden of obesityMean co
- Page 226 and 227:
15. Lacey LA, Wolf A, O'shea D, Ern
- Page 228 and 229:
Author Contribution StatementsPaula